Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00583362 · ClinicalTrials.gov registry record · Phase 2
A Continuation Trial for Subjects With Systemic Lupus Erythematosus That Have Completed Protocol LBSL02
A Phase 2 study, sponsored by Human Genome Sciences Inc., a GSK Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 298
- Enrollment target
NCT00583362 is a Phase 2 study that has completed, run by Human Genome Sciences Inc., a GSK Company. The registered enrollment target is 298 participants.
The verdict
NCT00583362, a Phase 2 study, has completed, sponsored by Human Genome Sciences Inc., a GSK Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 298 participants
- Enrollment target
Study Summary
This is a continuation study to evaluate the long-term safety and efficacy of LymphoStat-B™ in subjects with SLE disease, that completed study LBSL02 and benefitted from treatment.
Interventions
- BIOLOGICAL Belimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 298 participants |
| Start Date | 2005-05-04 |
| Est. Completion | 2016-02-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00583362
The ClinicalTrials.gov registry entry for NCT00583362 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 298 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Human Genome Sciences Inc., a GSK Company, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Belimumab is the first listed.
NCT00583362 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00583362 about?
NCT00583362 is a clinical study titled "A Continuation Trial for Subjects With Systemic Lupus Erythematosus That Have Completed Protocol LBSL02". This is a continuation study to evaluate the long-term safety and efficacy of LymphoStat-B™ in subjects with SLE disease, that completed study LBSL02 and benefitted from treatment.
What is the current status of trial NCT00583362?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 298 participants. The study started on 2005-05-04. Estimated completion is 2016-02-23.
What interventions are being tested in trial NCT00583362?
The interventions under investigation include: Belimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00583362?
This trial is sponsored by Human Genome Sciences Inc., a GSK Company, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.